Use of myostatin inhibitors and combination therapies
The present disclosure relates to the treatment of muscle conditions, such as SMA, with the use of an agent that inhibits myostatin signaling. The disclosure includes combination therapies that include a myostatin inhibitor and a neuronal corrector.
1. A method of treating a neuromuscular disease in a subject, the method comprising administering to the subject a myostatin inhibitor and a neuronal corrector therapy in amounts effective to treat the neuromuscular disease,
wherein:
i) the neuromuscular disease affects a target muscle that is in an anabolic state;
ii) the subject has impaired neurological signaling between a motor neuron and a target muscle, wherein the target muscle has retained or regained at least partial functional innervation by the motor neuron; and
iii) the neuromuscular disease affects a target muscle that is enriched with type II fibers;
wherein the subject receives the myostatin inhibitor and the neuronal corrector therapy within six months of one another;
wherein the neuronal corrector therapy comprises an agent capable of correcting a neuronal defect in the motor neuron; and
wherein the neuromuscular disease is spinal muscular atrophy (SMA).
2. The method of claim 1 , wherein the SMA is type I SMA, type II SMA, or type III SMA.
3. The method of claim 1 , wherein the subject is a pediatric subject or a young adult who is still growing and anabolically active.
4. The method of claim 1 , wherein the myostatin inhibitor inhibits cleavage of a myostatin prodomain, inhibits release of a mature myostatin growth factor, and/or inhibits activation of a pro or latent myostatin to a mature myostatin.
5. The method of claim 1 , wherein the myostatin inhibitor is administered in an amount effective to:
a) delay or alleviate muscle atrophy;
b) delay loss of α-motor neurons;
c) prevent or delay expression of immature muscle markers;
d) prevent, alleviate, or delay intramuscular fat deposits characterized by fatty replacement of muscle tissue;
e) increase an Expanded Hammersmith Functional Motor Scale score by ≥1 points as compared to untreated control, or, by ≥1 points from baseline measured prior to treatment;
f) delay progressive decrease of an Expanded Hammersmith Functional Motor Scale over a period of 12 months, 24 months, or 36 months;
g) increase a CHOP INTEND score by ≥1 points as compared to untreated control; and/or
h) increase a MFM-32 score by at least 1 points as compared to untreated control.
6. The method of claim 1 , wherein the neuronal corrector therapy comprises an SMN corrector and/or an anabolic stimulator.
7. The method of claim 1 , wherein the neuronal defect in the motor neuron is a genetic defect.
8. A method of treating spinal muscular atrophy (SMA) in a subject, the method comprising:
(i) selecting a subject, wherein the subject has SMA and is a pediatric subject or a young adult who is still growing and anabolically active; and
(ii) administering to the subject a selective myostatin inhibitor and an SMN corrector therapy in amounts effective to treat SMA.
9. The method of claim 8 , wherein the SMA is type I SMA, type II SMA, or type III SMA.
10. The method of claim 8 , wherein the myostatin inhibitor and the SMN corrector therapy are administered concurrently or within six months of one another.
11. The method of claim 8 , wherein the SMN corrector therapy comprises a splice modifier.
12. The method of claim 8 , wherein the SMN corrector therapy comprises an SMN gene replacement or gene therapy.
13. The method of claim 8 , wherein the SMN corrector therapy comprises an SMN transcription enhancer.
14. The method of claim 8 , wherein the SMN corrector therapy comprises an SMN protein translation enhancer.
15. The method of claim 8 , wherein the SMN corrector therapy comprises an SMN protein stabilizer.
16. A method of treating spinal muscular atrophy (SMA) in a subject, the method comprising:
(i) selecting a subject, wherein the subject: (a) has SMA and is a pediatric subject or a young adult who is still growing and anabolically active; and (b) is on an SMN corrector therapy; and
(ii) administering to the subject a selective myostatin inhibitor in an amount effective to treat SMA.
17. The method of claim 16 , wherein the SMA is type I SMA, type II SMA, or type III SMA.
18. The method of claim 16 , wherein the SMN corrector therapy comprises a splice modifier.
19. The method of claim 16 , wherein the SMN corrector therapy comprises an SMN gene replacement or gene therapy.
20. The method of claim 16 , wherein the SMN corrector therapy comprises an SMN transcription enhancer.
21. The method of claim 16 , wherein the SMN corrector therapy comprises an SMN protein translation enhancer.
22. The method of claim 16 , wherein the SMN corrector therapy comprises an SMN protein stabilizer.